TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Trinity Health Michigan
University of California, San Francisco
University of Washington
University of North Carolina, Chapel Hill
Alliance for Clinical Trials in Oncology
Providence Health & Services
City of Hope Medical Center
Washington University School of Medicine
Institut Bergonié
Pennington Biomedical Research Center
Trinity Health Michigan
Institut Bergonié
Institut Bergonié
Academic and Community Cancer Research United
Academic and Community Cancer Research United
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TheraOp
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asan Medical Center
Stanford University
University of Oxford
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Stanford University
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Asan Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Academic and Community Cancer Research United
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Wake Forest University Health Sciences
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ludwig Institute for Cancer Research
Karolinska Institutet
M.D. Anderson Cancer Center
Duke University
University of North Carolina, Chapel Hill
M.D. Anderson Cancer Center
Trinity Health Michigan
Dartmouth-Hitchcock Medical Center
Washington University School of Medicine
Alliance for Clinical Trials in Oncology
Institut Bergonié
Fred Hutchinson Cancer Center
Abramson Cancer Center at Penn Medicine